Antistaphylococcal agents commonly lack activity against Gram-negative bacteria like Escherichia coli owing to the permeability barrier presented by the outer membrane and/or the action of efflux transporters. When these intrinsic resistance mechanisms are artificially compromised, such agents almost invariably demonstrate antibacterial activity against Gram negatives. Here we show that this is not the case for the antibiotic daptomycin, whose target appears to be absent from E. coli and other Gram-negative pathogens.
A ntibiotic resistance is a growing problem that negatively impacts our ability to treat bacterial infection. The situation is becoming particularly grave in the case of Gram-negative pathogens (1) , which, in contrast to Gram-positive bacteria, are intrinsically insusceptible to many classes of antibacterial agents owing to the permeability barrier presented by the outer membrane (OM) and/or the action of efflux transporters (2) . One approach for developing novel treatments against Gram-negative bacteria involves the identification of compounds capable of disrupting these intrinsic resistance mechanisms, with a view to rendering these organisms susceptible to existing anti-Gram-positive drugs. The concept of combining such potentiator or adjuvant compounds with established antibacterial drugs has shown considerable promise in in vitro studies (3) . For example, colistin potentiates the activity of glycopeptides against a range of Gram-negative pathogens, presumably by disrupting the OM (4), and high-throughput screening has identified several compounds which enhance the activity of novobiocin against Escherichia coli by increasing cell permeability (5) . Furthermore, inhibitors of efflux sensitize Gram-negative organisms to a variety of antistaphylococcal agents, including linezolid and macrolides (6, 7) . In this study, we show that, while most antistaphylococcal agents are active against Gram-negative bacteria provided they are allowed to reach their target, this is not true of the lipopeptide antibiotic daptomycin.
Antibacterial agents and chemicals used in this study were from Sigma-Aldrich (Poole, United Kingdom), with the exception of vancomycin (LEK pharmaceuticals, Ljubljana, Slovenia), nisin (NBS Biologicals Ltd., Huntingdon, United Kingdom), flucloxacillin (CP Pharmaceuticals Ltd., Wrexham, United Kingdom), indolmycin and linezolid (Pfizer, Kalamazoo, MI), and daptomycin (Cubist Pharmaceuticals, Lexington, MA). Susceptibility determinations were performed by broth microdilution in Mueller-Hinton broth (MHB) according to CLSI guidelines (8) , supplemented with 50 g/ml Ca 2ϩ in the case of daptomycin. Against the standard laboratory E. coli strain 1411 (9), with its intrinsic resistance mechanisms intact, most of the antistaphylococcal agents tested had little or no detectable antibacterial activity (Table 1) . However, upon permeabilizing the OM of this strain with polymyxin B nonapeptide (PMBN; 4 g/ml), the antibacterial activity increased considerably for the majority of compounds (Table 1) . These results are consistent with previous observations that the OM acts as a barrier to hydrophobic compounds or those with a molecular weight Ͼ600 Da (2). Insertional inactivation of acrAB (9) also increased the antibacterial activity of many of the agents tested, implying that they are ordinarily substrates for the AcrAB-TolC efflux transporter (Table 1) . Some antistaphylococcal agents lack activity against E. coli exclusively owing to OM impermeability (e.g., clofazimine), others primarily as a consequence of AcrAB-TolC-mediated efflux (e.g., linezolid), and still others as a result of both intrinsic resistance mechanisms (e.g., mupirocin) ( Table 1) .
The observed inability to sensitize E. coli to the antistaphylococcal agents clindamycin, daptomycin, streptomycin, and vancomycin suggests either that the OM is not a primary barrier to activity for these compounds or that sufficient OM remained after PMBN treatment to restrict access of these drugs to their targets. To examine the antibacterial activity of these agents in the absence of the E. coli OM, we generated protoplasts of E. coli 1411 (11) . A protoplasting efficiency of ϳ99% was achieved, and protoplast preparations were diluted 1:10,000 in MHB containing 0.5 M sucrose to ensure removal by dilution of any cells retaining an intact OM. Susceptibility determinations with protoplasts were conducted as for whole cells, although MHB was supplemented with 0.5 M sucrose to maintain protoplast integrity. The activity of clindamycin, streptomycin, and vancomycin against protoplasts increased Ն8-fold over that against PMBN-treated cells ( Table 1) , demonstrating that the OM does ordinarily act to limit the activity of these antibiotics against E. coli. In contrast, daptomycin remained inactive against E. coli protoplasts ( Table 1) .
The antibacterial target of daptomycin in Staphylococcus aureus and other Gram-positive bacteria is the cytoplasmic membrane (CM) (12) . Daptomycin inserts into the CM in a Ca 2ϩ -dependent manner, resulting in membrane depolarization and subsequent loss of intracellular components, including K ϩ , Mg 2ϩ , and ATP (12) . The presence of Ca 2ϩ has been proposed to permit the interaction between the anionic daptomycin and the negatively charged phospholipids within the Gram-positive CM (13) .
The content of negatively charged phospholipid in the CM of E. coli is substantially lower (30%) than that found in Gram-positive organisms such as S. aureus (100%) (14) . As a consequence, daptomycin may lack activity against permeabilized E. coli simply because it cannot interact with, or does not disrupt, the Gram-negative CM. To confirm this, we assessed the ability of daptomycin to compromise the integrity of carboxyfluorescein-filled liposomes (15) (14) . Phospholipids were from Avanti polar lipids (Birmingham, AL). To assess liposome damage, 50 M S. aureus or E. coli liposomes were challenged for 10 min with doubling dilutions of daptomycin or clofazimine across a concentration range from 4 g/ml to 64 g/ml; clofazimine was employed as a positive control for liposome damage in these experiments since its mode of action involves direct damage to the CM (16) . The leakage of carboxyfluorescein from liposomes was monitored at 485 nm, and percent liposome integrity was calculated relative to liposomes challenged with 0.5% Triton X-100 (corresponding to 100% liposome damage [0% liposome integrity]). Exposure to clofazimine led to a comparable loss of integrity for both S. aureus and E. coli liposomes (Ͼ60% loss of integrity at concentrations Ն8 g clofazimine/ml) (Fig. 1) . Liposomes consisting of E. coli CM exhibited only a minor loss of integrity (up to 6%) when exposed to concentrations of daptomycin up to 64 g/ml in the presence of 50 g/ml Ca 2ϩ (Fig. 1) , and comparable results were obtained in the absence of Ca 2ϩ (data not shown). In contrast, staphylococcal liposomes underwent a loss of 38% integrity at 8 g daptomycin/ml, increasing to a 97% loss of integrity at 64 g daptomycin/ml (Fig.  1) , an effect which was dependent on the presence of Ca 2ϩ (data not shown). Thus, the limited ability of daptomycin to damage the E. coli CM compared with that of S. aureus appears to be directly attributable to the differences in phospholipid composition.
Since the CMs of other Gram-negative pathogens contain similar proportions of anionic phospholipid to that of E. coli (17) , we reasoned that daptomycin would be equally ineffective against the CMs of these organisms. To assess this, we determined the susceptibility to daptomycin and clofazimine of both whole cells and protoplasts of Enterobacter cloacae ATCC 13047, Pseudomonas aeruginosa PAO1, Klebsiella pneumoniae, Moraxella catarrhalis, and Salmonella enterica serovar Typhimurium (clinical isolates from the Leeds General Infirmary, Leeds, United Kingdom). As for E. coli, clofazimine only demonstrated activity against these Gram-negative species once the OM had been compromised (Table 2). Daptomycin did not demonstrate detectable antibacterial activity against any of these species, even after the removal of the OM (Table 2) . 
FIG 1
The effect of daptomycin (with 50 g/ml Ca 2ϩ ) and clofazimine on S. aureus and E. coli liposome integrity after a 10-min challenge. Error bars represent standard deviations from the means for three independent experiments.
In conclusion, while we have not ruled out the possibility that the OM and/or efflux transporters may act to restrict the accumulation of daptomycin in Gram-negative bacteria, it is clear that these intrinsic resistance mechanisms are not responsible for the observed lack of anti-Gram-negative activity of this antibiotic. Instead, the CM of Gram-negative bacteria is insusceptible to daptomycin. This is likely due to the lower proportion of anionic phospholipids in the Gram-negative CM compared to S. aureus, resulting in insufficient sites for Ca 2ϩ -mediated insertion of daptomycin to prompt an antibacterial effect. Daptomycin is therefore unusual among antistaphylococcal agents in that its target appears to be absent from Gram-negative bacteria: it cannot therefore be considered a potential chemotherapeutic agent against Gram-negative pathogens, even in combination with potentiator compounds that act to compromise the intrinsic resistance mechanisms of these organisms. 
